Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMABRXY)

Drug Name
IDM-2101 Drug Info
Indication
Disease Entry ICD 11 Status REF
Colorectal cancer 2B91.Z Phase 2 [1]
Cross-matching ID
TTD Drug ID
DMABRXY

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Carcinoembryonic antigen CEA (CD66e) TTY6DTE CEAM5_HUMAN Not Available [1]
Melanoma-associated antigen 3 (MAGEA3) TTWSKHD MAGA3_HUMAN Not Available [1]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Carcinoembryonic antigen CEA (CD66e) DTT CEACAM5 5.812 11.49 6.112 6.957
Melanoma-associated antigen 3 (MAGEA3) DTT MAGEA3 5.456 3.433 5.396 5.802
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Colorectal cancer
ICD Disease Classification 2B91.Z
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Carcinoembryonic antigen CEA (CD66e) DTT CEACAM5 6.68E-91 0.29 1.07
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 Induction of immune responses and clinical efficacy in a phase II trial of IDM-2101, a 10-epitope cytotoxic T-lymphocyte vaccine, in metastatic non-small-cell lung cancer. J Clin Oncol. 2008 Sep 20;26(27):4418-25.